Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:HSKANASDAQ:MYGNNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$20.82-0.5%$19.13$14.40▼$47.00$1.38B1.33917,065 shs210,861 shsHSKAHeska$119.99$119.09$57.83▼$120.03$1.31B1.58241,932 shsN/AMYGNMyriad Genetics$5.16-1.3%$6.03$3.81▼$29.30$475.63M1.841.71 million shs234,844 shsNTLAIntellia Therapeutics$8.49+0.2%$7.98$5.90▼$28.18$877.87M2.142.79 million shs1.27 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+1.01%+5.28%+14.13%-1.18%-39.61%HSKAHeska0.00%0.00%0.00%0.00%0.00%MYGNMyriad Genetics+0.77%+7.17%+34.45%-49.76%-76.43%NTLAIntellia Therapeutics+2.29%+10.14%+4.31%-11.95%-63.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.7872 of 5 stars4.50.00.00.02.80.00.0HSKAHeskaN/AN/AN/AN/AN/AN/AN/AN/AMYGNMyriad Genetics4.0927 of 5 stars4.11.00.04.12.21.70.6NTLAIntellia Therapeutics4.6385 of 5 stars4.31.00.04.72.62.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90158.95% UpsideHSKAHeska 0.00N/AN/AN/AMYGNMyriad Genetics 2.13Hold$14.38178.77% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$34.95311.76% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, CLDX, HSKA, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M182.80N/AN/A$9.08 per share2.29HSKAHeska$257.31M5.09$1.69 per share70.99$39.00 per share3.08MYGNMyriad Genetics$831.30M0.57N/AN/A$9.53 per share0.54NTLAIntellia Therapeutics$45.57M19.29N/AN/A$11.73 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/6/2025 (Estimated)HSKAHeska-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/AMYGNMyriad Genetics-$263.30M-$1.12N/AN/AN/A-14.09%-4.51%-3.07%8/5/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%8/14/2025 (Estimated)Latest MYGN, CLDX, HSKA, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AHSKAHeskaN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27HSKAHeska0.235.644.12MYGNMyriad Genetics0.051.901.73NTLAIntellia TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AHSKAHeska99.01%MYGNMyriad Genetics99.02%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%HSKAHeska12.30%MYGNMyriad Genetics2.10%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableHSKAHeska80810.91 million9.57 millionNot OptionableMYGNMyriad Genetics2,60092.18 million89.12 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableMYGN, CLDX, HSKA, and NTLA HeadlinesRecent News About These CompaniesCantor Fitzgerald Estimates NTLA FY2026 EarningsJune 11 at 2:23 AM | americanbankingnews.comBrokers Issue Forecasts for NTLA FY2026 EarningsJune 10 at 8:56 AM | marketbeat.comIntellia Therapeutics Inc.June 9 at 8:41 AM | barrons.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $34.95 Average PT from AnalystsJune 7, 2025 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?June 6, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity GroupJune 5, 2025 | americanbankingnews.comHow Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%June 4, 2025 | zacks.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Wellington Management Group LLPJune 4, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 3, 2025 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)June 1, 2025 | theglobeandmail.comSquarepoint Ops LLC Has $1.18 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 1, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.6% - Here's What HappenedMay 31, 2025 | marketbeat.comSA analyst downgrades: PLTR, PSTG, NTLA, ARWRMay 30, 2025 | msn.comIntellia shares tumble on safety signal in gene-editing trialMay 30, 2025 | thepharmaletter.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 4.7% - Here's What HappenedMay 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from WedbushMay 30, 2025 | marketbeat.comNTLA Stock Down as Patient Faces Adverse Event in Gene Therapy StudyMay 30, 2025 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?May 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, CLDX, HSKA, and NTLA Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$20.82 -0.11 (-0.50%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Heska NASDAQ:HSKAHeska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.Myriad Genetics NASDAQ:MYGN$5.16 -0.07 (-1.34%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Intellia Therapeutics NASDAQ:NTLA$8.49 +0.02 (+0.21%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Will Warner Bros. Discovery’s Split Produce Double the Upside? Is a Summer Slowdown Ahead for Microsoft Stock? CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
